Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Zenidolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 6/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.97 |
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.35 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.35 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zenidolol SCHEMBL31074300 | 1.00 | ADRB2 (1.00) | ADRB2NPSR1MEN1LMNAPMP22 | |
| Zenidolol SCHEMBL29686378 | 1.00 | ADRB2 (1.00) | ADRB2NPSR1MEN1LMNAPMP22 | |
| Zenidolol SCHEMBL146178 | 0.99 | ADRB2 (1.00) | ADRB2NPSR1MEN1LMNAPMP22 | |
| Zenidolol SCHEMBL29387637 | 0.99 | ADRB2 (1.00) | ADRB2NPSR1MEN1LMNAPMP22 | |
| Zenidolol SCHEMBL29558331 | 0.99 | ADRB2 (1.00) | ADRB2NPSR1MEN1LMNAPMP22 | |
| Zenidolol SCHEMBL14941581 | 0.99 | ADRB2 (1.00) | ADRB2NPSR1MEN1LMNAPMP22 | |
| Zenidolol SCHEMBL8027938 | 0.99 | ADRB2 (1.00) | ADRB2NPSR1MEN1LMNAPMP22 | |
| Zenidolol SCHEMBL15058356 | 0.99 | ADRB2 (1.00) | ADRB2NPSR1MEN1LMNAPMP22 | |
| SCHEMBL15549338 | 0.84 | ADRB2 (0.74) | ADRB2NPSR1MEN1LMNAPMP22 | |
| SCHEMBL11266032 | 0.84 | ADRB2 (0.74) | ADRB2NPSR1MEN1LMNAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622951-A1 | SELECTIVE BETA2-ADRENOCEPTOR ANTAGONIST | Trio Medicines Limited (GB) | 2025-10-01 | — | — | EP | disclosed |
| CN-119950731-A | Medicine for treating cerebral hemorrhage and improving nerve prognosis and application thereof | 郑州大学 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024110583-A1 | SELECTIVE β2-ADRENOCEPTOR ANTAGONIST | TRIO MEDICINES LIMITED (GB) | 2024-05-30 | — | — | WO | disclosed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-7217724-B2 | Indole, indazole, and benzazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20060063762-A1 | Indole indazole and benzazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1514869-A1 | INDOLE, INDAZOLE, AND BENZAZOLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-0872246-B1 | DRUG FOR RELIEVING PAIN AND PROMOTING THE REMOVAL OF CALCULI IN UROLITHIASIS | KISSEI PHARMACEUTICAL (JP) | 2003-02-19 | — | — | EP | disclosed |
| US-6410560-B1 | Drug for relieving pain and promoting the removal of calculi in urolithiasis | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6376513-B1 | Drug for relieving pain and promoting the removal of calculi in urolithiasis | KISSEI PHARMACEUTICALS CO., LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| EP-0958835-A1 | PREVENTIVE/REMEDY FOR FREQUENT URINATION AND URINARY INCONTINENCE | Kissei Pharmaceutical Co., Ltd. (JP) | 1999-11-24 | — | — | EP | disclosed |
| EP-0003664-B1 | ALKANOLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-02-17 | — | — | EP | disclosed |
| US-4275058-A | 1-(7-METHYLINDAN-4-YLOXY)-3-ISOPROPYLAMINOBUTAN-2-OL | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-06-23 | — | — | US | disclosed |
| EP-0003664-A1 | Alkanolamine derivatives, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063762-A1 | Indole indazole and benzazole derivative | ADRB3, ADRA2C, ADRB2 | ADRB2 3/4885ADRB1 4/4885ADRB3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.